TRK-250

Status
Phase 1
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Inhaled Drug
Funder Type
Industry

Drug Details

TRK-250/BNC-1021 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, a key growth factor involved in lung fibrosis, at the gene expression level. One of the features of the agent is that it is a single strand long-chain nucleic acid with a unique molecular structure employing BONAC’s proprietary nucleic acid platform, and it is expected to be a new nucleic acid medicine that has overcome the issue of stability. Moreover, it is in an aerosol form that can be administered directly to the lung, which is expected to carry the agent efficiently to the target organ.

Study Purpose

TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >